Edward Byrd – Trademark Portfolio

Entity Type: 01

Edward Byrd holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 45 (Legal & Security Services) across 2 Nice Classification classes. Currently, 3 trademarks are registered and 5 are pending. Notable registered marks include MITOINTEL, MITELLIGEN, and POWER YOUR MIND, TRANSFORM YOUR LIFE. The owner is based in Tomales, CA.

P.O. Box 367

Tomales, CA 94971

8 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Edward Byrd's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

45
Legal & Security Services (1 filing)

Legal services; security services for the protection of property and individuals

Frequently Asked Questions

How many trademarks does Edward Byrd have?

Edward Byrd has 8 U.S. trademarks filed with the USPTO. Of these, 3 registered, 5 pending.

What trademark classes does Edward Byrd file in?

Edward Byrd files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 45 (Legal & Security Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Edward Byrd's most well-known trademarks?

Edward Byrd's registered trademark portfolio includes well-known marks such as MITOINTEL, MITELLIGEN, and POWER YOUR MIND, TRANSFORM YOUR LIFE. These are among 3 currently registered trademarks in the portfolio.

What is Edward Byrd's trademark registration success rate?

Edward Byrd has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 5 applications are pending review.